Evidence mapPaperPMID 41382274Full record

ReviewCardiovascular diabetology. Endocrinology reports2025

Chronic hyperglycemia and cardiovascular dysfunction: an in-depth exploration of metabolic and cellular pathways in type 2 diabetes mellitus.

Araiz Hussain

Abstract readReview
In one paragraph

Review in Cardiovascular diabetology. Endocrinology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Araiz HussainDepartment of Pharmacy, Benazir Bhutto Shaheed University Lyari, Karachi, Pakistan. araizhussain85@gmail.com.ORCID http://orcid.org/0009-0009-0266-8489

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hyperglycemia is the defining feature of type 2 diabetes mellitus (T2DM) and a central driver of its long-term complications, including microvascular and macrovascular diseases. Among these, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with T2DM. Persistent glucose elevation activates multiple interrelated biochemical pathways, including the polyol pathway, formation of advanced glycation end-products, protein kinase C activation, oxidative stress via several cellular mechanisms, as well as the hexosamine biosynthetic pathway. These processes collectively promote excessive oxidative damage, endothelial dysfunction, inflammation, and adverse cardiac remodeling, ultimately accelerating cardiovascular damage. Research has further revealed that hyperglycemia imprints long-lasting molecular changes through metabolic memory, largely mediated by epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNAs, and sustaining vascular dysfunction even after glycemic control. Building on both classical and emerging evidence, this review synthesizes advances in understanding hyperglycemia-induced vascular damage and highlights promising therapeutic targets within these pathways. Strategies under investigation include inhibitors of enzymatic reactive oxygen species sources, modulators of mitochondrial dynamics and function, regulators of protein kinase C, blockers of glycation pathways, and epidrugs targeting epigenetic modifications. By integrating these mechanistic insights with therapeutic innovation, the field is shifting from a narrow focus on glucose lowering to a broader approach aimed at preventing and potentially reversing the vascular complications of diabetes. This perspective emphasizes the urgent need for pathway-specific therapeutic strategies to effectively address the cardiovascular burden of T2DM.

Indexed as

Advanced glycation end-productsCardiovascular diseaseEpigenetic modificationsHexosamine biosynthetic pathwayHyperglycemiaOxidative stressPolyol pathwayProtein kinase CType 2 diabetes mellitus

Identifiers

PMID41382274
PMCPMC12699840

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.